Multiple sclerosis (MS) disease-modifying therapies (DMTs) represent a significant portion of a health plan’s total spend. Several of these DMTs are infused treatments that must be administered by a physician and therefore incur additional costs, such as markups on the drug price and administration related costs. This paper examines the cost dispersion of one infused DMT treatment, ocrelizumab, by site of service for patients with commercial insurance, a major insurance segment for MS patients.

This article was commissioned by Novartis Pharmaceuticals Corporation.